<!DOCTYPE html>
<html>
<head>
    <title>China ad&#xAD;min&#xAD;is&#xAD;ters 4m doses of two lo&#xAD;cal vac&#xAD;cines in emer&#xAD;gency scheme - PressReader</title>
    <meta name="description" content="">
    <meta content="magazines, newspapers, digital news, reading, news, breaking news, newspaper online" name="keywords">
    <meta name="Robots" content="NOARCHIVE,NOODP">
    <meta charset="UTF-8">
    <meta http-equiv="Content-type" content="text/html; charset=utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    
    <link rel="canonical" href="/singapore/the-straits-times/20210110/281663962643605" />


    <style>
        li {
            margin: 1em 0;
        }
        img {
            max-width: 100%;
        }
        p, h1, h2, h3 {
            max-width: 100%;
        }
    </style>
</head>
<body>
    <div>
        

<article>
    <h1>China ad&#xAD;min&#xAD;is&#xAD;ters 4m doses of two lo&#xAD;cal vac&#xAD;cines in emer&#xAD;gency scheme</h1>
    <h2></h2>
    <section>
        <a href="/singapore/the-straits-times/textview" title="The Straits Times">The Straits Times</a>
        - <a href="/singapore/the-straits-times/20210110/textview" title="The Straits Times - 2021-01-10"><time>2021-01-10</time></a>
        - <span>THE BIG STORY</span>
        - <span role="byline"></span>
    </section>

    <p>BEI­JING • More than four mil­lion Covid-19 vac­cine doses from the China Na­tional Biotec Group (CNBG) have been ad­min­is­tered as at Jan 4 via China’s emer­gency use pro­gramme, the com­pany’s par­ent firm said last Thurs­day.</p>
    <p>Two vac­cines re­spec­tively from two in­sti­tutes owned by CNBG, a unit of state-backed China Na­tional Phar­ma­ceu­ti­cal Group (Sinopharm), are in­cluded in China’s emer­gency vac­ci­na­tion scheme, which started in July tar­get­ing spe­cific groups of people fac­ing a high in­fec­tion risk.</p>
    <p>“No se­ri­ous ad­verse re­ac­tion was re­ported in large-scale emer­gency use of Sinopharm’s Covid-19 vac­cines,” Sinopharm said on Chi­nese social me­dia WeChat.</p>
    <p>A to­tal of 72,000 people have been over­seas af­ter re­ceiv­ing the emer­gency jabs, in­clud­ing around 40 per cent of more than 5,000 staff on one Chi­nese firm’s Pak­istan-based project, Sinopharm said.</p>
    <p>None of the vac­ci­nated diplo</p>
    <p>mats, in­ter­na­tional or­gan­i­sa­tion rep­re­sen­ta­tives or em­ploy­ees at Chi­nese firms who went to coun­tries of high virus risk con­tracted Covid-19, de­spite their close con­tact with in­fected lo­cals, ac­cord­ing to Sinopharm.</p>
    <p>The firm did not break down the num­ber of doses for each of the two vac­cines used in the emer­gency pro­gramme.</p>
    <p>Aside from CNBG’s two vac­cines, China’s emer­gency use pro­gramme also in­cludes a po­ten­tial shot from Si­no­vac Biotech.</p>
    <p>A fourth can­di­date from CanSino Bi­o­log­ics was ap­proved for use in the Chi­nese mil­i­tary.</p>
    <p>The vac­cine from the Bei­jing In­sti­tute of Bi­o­log­i­cal Prod­ucts, a unit of CNBG, was ap­proved in China for broader use among the gen­eral public last year.</p>
    <p>The two-dose reg­i­men is 79.34 per cent ef­fec­tive against the disease, ac­cord­ing to in­terim anal­y­sis from late-stage clin­i­cal tri­als over­seas.</p>
    <p>Although the CNBG vac­cine’s pro­tec­tion rate is lower than the more than 90 per cent ef­fi­cacy of vac­cines from Moderna or Pfizer and its part­ner BioN­Tech, it can be trans­ported and stored at less de­mand­ing tem­per­a­tures.</p>

    <div>
        <picture>
            <img src="https://i.prcdn.co/img?regionKey=7gLJLan2j1%2bnOPSD9RXUsg%3d%3d" />
        </picture>
        <span role="byline">PHOTO: AGENCE FRANCE-PRESSE</span>
        <p data-role="text">People get&#xAD;ting a Covid-19 vac&#xAD;cine at a tem&#xAD;po&#xAD;rary vac&#xAD;ci&#xAD;na&#xAD;tion cen&#xAD;tre in Bei&#xAD;jing on Fri&#xAD;day. Two vac&#xAD;cines from two in&#xAD;sti&#xAD;tutes owned by the China Na&#xAD;tional Biotec Group, a unit of state-backed China Na&#xAD;tional Phar&#xAD;ma&#xAD;ceu&#xAD;ti&#xAD;cal Group, are in&#xAD;cluded in China&#x2019;s emer&#xAD;gency vac&#xAD;ci&#xAD;na&#xAD;tion scheme. The pro&#xAD;gramme, which started in July, also in&#xAD;cludes a po&#xAD;ten&#xAD;tial shot from Si&#xAD;no&#xAD;vac Biotech.</p>
    </div>

</article>

<section>
    <h3><a href="/catalog/language/english">Newspapers in English</a></h3>
    <h3><a href="/catalog/country/singapore">Newspapers from Singapore</a></h3>
</section>

    </div>
    
    <p><a href="http://www.pressreader.com">© PressReader. All rights reserved.</a></p>

        <script>
            (function (i, s, o, g, r, a, m) {
                i['GoogleAnalyticsObject'] = r; i[r] = i[r] || function () {
                    (i[r].q = i[r].q || []).push(arguments);
                }, i[r].l = 1 * new Date();
                a = s.createElement(o), m = s.getElementsByTagName(o)[0]; a.async = 1; a.src = g;
                m.parentNode.insertBefore(a, m);
            })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
        </script>
        <script>
            ga('create', 'UA-44408245-1');
            ga('send', 'pageView');
        </script>
</body>
</html>
